Live webinar recorded April 29, 2016 - http://www.alzforum.org/webinars/learn-about-ad-biomarker-meta-analysis-alzbiomarker-database

1. WEBINAR
Learn About AD Biomarker Meta-Analysis
on AlzBiomarker Database
Johannes Streffer, M.D.
Senior Director, Alzheimer's Disease Clinical Development
Janssen, Pharmaceutical companies of JNJ
Friday, April 29, 2016 at 01:00 PM US EDT

2. “However, several drug candidates targeting Aβ have not been successful in large,
multicentre clinical trials, and it is now generally acknowledged that this is partly because
a large proportion of clinically diagnosed patients show no evidence of amyloid pathology”
• Critical review
– Elucidating the role and validity of CSF biomarkers in diagnosis of Alzheimer’s
disease
• Biomarkers are critical for
– “positive” and correct diagnosis of Alzheimer disease
– early diagnosis and definition of new (pre dementia) populations
– Potential roles in assessing treatment response
2

3. “The negative scans for amyloid in 36% of APOE ε4 noncarriers at baseline
raises concern about the reliability of diagnoses of Alzheimer’s disease among
noncarriers and suggests the possible usefulness of incorporating amyloid
thresholds into eligibility criteria in future trials of anti-amyloid therapy.”
3

4. Development of new frame work description
for Preclinical/Prodromal/ Early Alzheimer’s Disease is critically
dependent on biomarkers
4

5. 06.03.2010CHEMPHARM DEVELOPMENT | Finding New Opportunities 5
Liu, E., et al (2014) Alzheimer's & Dementia: The Journal of the Alzheimer's Association 10, P353.

6. WEBINAR
Learn About AD Biomarker Meta-Analysis
on AlzBiomarker Database
Johannes Streffer, M.D.
Senior Director, Alzheimer's Disease Clinical Development
Janssen, Pharmaceutical companies of JNJ
Friday, April 29, 2016 at 01:00 PM US EDT